Show simple item record

dc.contributor.authorRoberts, AW
dc.contributor.authorSeymour, JF
dc.contributor.authorBrown, JR
dc.contributor.authorWierda, WG
dc.contributor.authorKipps, TJ
dc.contributor.authorKhaw, SL
dc.contributor.authorCarney, DA
dc.contributor.authorHe, SZ
dc.contributor.authorHuang, DCS
dc.contributor.authorXiong, H
dc.contributor.authorCui, Y
dc.contributor.authorBusman, TA
dc.contributor.authorMcKeegan, EM
dc.contributor.authorKrivoshik, AP
dc.contributor.authorEnschede, SH
dc.contributor.authorHumerickhouse, R
dc.date.available2014-05-22T07:56:07Z
dc.date.issued2012-02-10
dc.identifierpii: JCO.2011.34.7898
dc.identifier.citationRoberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S. Z., Huang, D. C. S., Xiong, H., Cui, Y., Busman, T. A., McKeegan, E. M., Krivoshik, A. P., Enschede, S. H. & Humerickhouse, R. (2012). Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease. JOURNAL OF CLINICAL ONCOLOGY, 30 (5), pp.488-496. https://doi.org/10.1200/JCO.2011.34.7898.
dc.identifier.issn0732-183X
dc.identifier.urihttp://hdl.handle.net/11343/33074
dc.descriptionC1 - Journal Articles Refereed
dc.description.abstractPURPOSE: BCL2 overexpression is a hallmark of chronic lymphocytic leukemia (CLL). The novel BH3 mimetic navitoclax (ABT-263) specifically inhibits BCL2 and related proteins BCL-x(l) and BCL-w, potently inducing apoptosis of CLL cells in vitro. A phase I trial in patients with CLL was conducted to evaluate the safety, pharmacokinetics, and biologic activity of oral navitoclax. PATIENTS AND METHODS: Twenty-nine patients with relapsed or refractory CLL received daily navitoclax for 14 days (10, 110, 200, or 250 mg/d; n = 15) or 21 days (125, 200, 250, or 300 mg/d; n = 14) of each 21-day cycle. Dose escalation decisions were informed by continual reassessment methodology. RESULTS: Lymphocytosis was reduced by more than 50% in 19 of 21 patients with baseline lymphocytosis. Among 26 patients treated with navitoclax ≥ 110 mg/d, nine (35%) achieved a partial response and seven maintained stable disease for more than 6 months. Median treatment duration was 7 months (range, 1 to ≥ 29 months). Median progression-free survival was 25 months. Activity was observed in patients with fludarabine-refractory disease, bulky adenopathy, and del(17p) CLL. Thrombocytopenia due to BCL-x(l) inhibition was the major dose-limiting toxicity and was dose-related. Low MCL1 expression and high BIM:MCL1 or BIM:BCL2 ratios in leukemic cells correlated with response. We determined that the navitoclax dose of 250 mg/d in a continuous dosing schedule was optimal for phase II studies. CONCLUSION: BCL2 is a valid therapeutic target in CLL, and its inhibition by navitoclax warrants further evaluation as monotherapy and in combination in this disease.
dc.formatapplication/pdf
dc.languageEnglish
dc.publisherAMER SOC CLINICAL ONCOLOGY
dc.subjectChemotherapy; Haematological Tumours; Molecular Targets; Cancer and Related Disorders
dc.titleSubstantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
dc.typeJournal Article
dc.identifier.doi10.1200/JCO.2011.34.7898
melbourne.peerreviewPeer Reviewed
melbourne.affiliationThe University of Melbourne
melbourne.affiliation.departmentMedical Biology (W.E.H.I.)
melbourne.source.titleJournal of Clinical Oncology
melbourne.source.volume30
melbourne.source.issue5
melbourne.source.pages488-496
melbourne.publicationid185153
melbourne.elementsid396762
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979082
melbourne.contributor.authorSeymour, John
melbourne.contributor.authorKhaw, Seong
melbourne.contributor.authorRoberts, Andrew
melbourne.contributor.authorHuang, David
melbourne.contributor.authorCARNEY, DENNIS
melbourne.contributor.authorHe, Simon
dc.identifier.eissn1527-7755
melbourne.fieldofresearch321105 Chemotherapy
melbourne.fieldofresearch321106 Haematological tumours
melbourne.fieldofresearch321108 Molecular targets
melbourne.seocode200199 Clinical health not elsewhere classified
melbourne.accessrightsAccess this item via the Open Access location


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record